Jazz Pharmaceuticals plc – PT Raised to $208.00 (JAZZ)
Equities researchers at Piper Jaffray boosted their target price on shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) from $200.00 to $208.00 in a research report issued on Wednesday. Piper Jaffray’s price objective would suggest a potential upside of 53.17% from the stock’s previous close.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 10.10% on Wednesday, hitting $149.515. 1,661,461 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 1-year low of $76.29 and a 1-year high of $176.60. The stock has a 50-day moving average of $147.8 and a 200-day moving average of $145.4. The company has a market cap of $8.880 billion and a price-to-earnings ratio of 103.27.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 39.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.07 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at FBR Capital Markets cut their price target on shares of Jazz Pharmaceuticals plc – from $214.00 to $213.00 in a research note on Wednesday. Separately, analysts at Leerink Swann raised their price target on shares of Jazz Pharmaceuticals plc – from $177.00 to $181.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Jazz Pharmaceuticals plc – from $171.00 to $177.00 in a research note on Tuesday, July 29th. They now have an “outperform” rating on the stock. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $174.42.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.